{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:00:20Z","timestamp":1791896420029,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd002828","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2005,4,20]],"date-time":"2005-04-20T00:00:00Z","timestamp":1113955200000}}],"reference-count":50,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002828.pub2","type":"journal-article","created":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T10:35:41Z","timestamp":1114166141000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Corticosteroids for myasthenia gravis"],"prefix":"10.1002","volume":"2011","author":[{"given":"Christiane","family":"Schneider-Gold","sequence":"first","affiliation":[{"name":"University of G\u00f6ttingen; Department of Neurology; Robert-Koch-Str. 40 G\u00f6ttingen Germany 37075"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gajdos","sequence":"additional","affiliation":[{"name":"Hopital Raymond Poincar\u00e9 (APHP); Service de R\u00e9animation; 104, Boulevard Raymond Poincar\u00e9 92380 Garches Ile de France France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus V","family":"Toyka","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg; Neurology; Josef-Schneider-Str.11 W\u00fcrzburg Bavaria Germany 97080"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard R","family":"Hohlfeld","sequence":"additional","affiliation":[{"name":"University of Munich; Institute for Clinical Neuroimmunology; Munich Germany D-81366"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,20]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","article-title":"Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis","volume":"150","author":"Bromberg","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD002828.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","article-title":"A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of a second interim analysis. Myasthenia Gravis Clinical Study Group","volume":"56","author":"Myasthenia Gravis Clinical Study Group","year":"1993","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","article-title":"Alternate-day prednisone: preliminary report of a double-blind controlled study","volume":"274","author":"Howard","year":"1976","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"6","key":"10.1002\/14651858.CD002828.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/archneur.1964.00460200010002","article-title":"Corticotropin in treatment of ocular myasthenia; a controlled clinical trial","volume":"11","author":"Mount","year":"1964","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0006|cit6","unstructured":"Schuchardt V Kohler W Hund E Scheglmann K Fleischer E Jung K A randomized, controlled trial of high-dose intravenous immunoglobulin versus methylprednisolone in moderate exacerbations of myasthenia gravis: final analysis after early termination Data on file"},{"issue":"10","key":"10.1002\/14651858.CD002828.pub2-BIB0007|cit7","first-page":"612","article-title":"Effectiveness of steroid treatment in juvenile myasthenia gravis","volume":"36","author":"Zhang","year":"1998","journal-title":"Chinese Journal of Pediatrics"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0008|cit8","first-page":"28","article-title":"A prospective study of effectiveness and safety of long-term prednisone therapy in patients with myasthenia gravis","volume":"33","author":"Bu","year":"2000","journal-title":"Chinese Journal of Neurology"},{"issue":"15","key":"10.1002\/14651858.CD002828.pub2-BIB0009|cit9","first-page":"939","article-title":"Long-term effects of plasma exchanges in myasthenia. Results of a randomised study.","volume":"12","author":"Gajdos","year":"1983","journal-title":"La Presse M\u00e9dicale"},{"issue":"5","key":"10.1002\/14651858.CD002828.pub2-BIB0010|cit10","first-page":"227","article-title":"Prophylactic use of human Ig-GAM-preparations in patients on mechanical ventilation undergoing plasmapheresis: results of a randomised study","volume":"29","author":"Horstkotte","year":"1992","journal-title":"Intensivmedizin und Notfallmedizin"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"12","key":"10.1002\/14651858.CD002828.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-dose intravenous methylprednisolone in myasthenia gravis","volume":"42","author":"Arsura","year":"1985","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002828.pub2-BIB0013|cit13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005081.pub2","article-title":"Medical and surgical treatment for ocular myasthenia","author":"Benatar","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD002828.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD002828.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.22.6.603","article-title":"Corticosteroids in the management of severe generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy","volume":"22","author":"Brunner","year":"1972","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","article-title":"Ocular myasthenia: diagnostic and therapeutic problems","volume":"77","author":"Evoli","year":"1988","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"European Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002828.pub2-BIB0021|cit21","first-page":"91","article-title":"Treatment of myasthenia","volume":"153","author":"Gajdos","year":"1997","journal-title":"Revue Neurologique (Paris)"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0022|cit22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for myasthenia gravis","author":"Gajdos","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277.pub3","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.1971.tb30766.x","article-title":"The use of ACTH and corticosteroids in myasthenia gravis","volume":"183","author":"Genkins","year":"1971","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1749-6632.1981.tb33764.x","article-title":"The natural course of myasthenia gravis and effect of therapeutic measures","volume":"377","author":"Grob","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD002828.pub2-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005224.pub2","article-title":"Immunosuppressive agents for myasthenia gravis","author":"Hart","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0027|cit27","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1[updated September 2008] www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/B978-012125831-3\/50289-6","article-title":"Therapy of myasthenia gravis and myasthenic syndromes","volume-title":"Neurological disorders - course and treatment","author":"Hohlfeld","year":"2003"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis. Recommendations for clinical research standards. Task force of the Medical Scientific Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"(S1)","key":"10.1002\/14651858.CD002828.pub2-BIB0030|cit30","first-page":"51","article-title":"Myasthenia gravis: immunological mechanisms and immunotherapy","volume":"37","author":"Lewis","year":"1995","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002828.pub2-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006986.pub2","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","author":"Mehndiratta","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low dose FK506 in the treatment of myasthenia gravis. A randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0033|cit33","first-page":"127","volume-title":"Myasthenia gravis","author":"Oosterhuis","year":"1997"},{"issue":"6","key":"10.1002\/14651858.CD002828.pub2-BIB0034|cit34","first-page":"479","article-title":"Studies in myasthenia gravis: review of a twenty year experience in over 1200 patients","volume":"38","author":"Osserman","year":"1971","journal-title":"The Mount Sinai Journal of Medicine, New York"},{"issue":"6","key":"10.1002\/14651858.CD002828.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double- blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD002828.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jnnp.56.6.702","article-title":"Acute myopathy associated with large parenteral dose of corticosteroids in myasthenia gravis","volume":"56","author":"Panegyres","year":"1993","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD002828.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Annals of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD002828.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD002828.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002828.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000050768","article-title":"Mycophenolate mofetil in the therapy of severe myasthenia gravis","volume":"46","author":"Schneider","year":"2001","journal-title":"European Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002828.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment","volume":"290","author":"Seybold","year":"1974","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002828.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.34.2.170","article-title":"Myasthenia gravis: prolonged treatment with steroids","volume":"34","author":"Sghirlanzoni","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1001\/jama.1935.02760230013004","article-title":"Myasthenia gravis: Effect of treatment with anterior pituitary extract","volume":"104","author":"Simon","year":"1935","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0044|cit44","first-page":"78","article-title":"The effects of anterior pituitary adrenocorticotrophic hormone (ACTH) in myasthenia gravis with tumor of the thymus","volume":"15","author":"Soffler","year":"1948","journal-title":"Journal of Mount Sinai Hospital"},{"issue":"2","key":"10.1002\/14651858.CD002828.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD002828.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis : clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD002828.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002828.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD002828.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1749-6632.1966.tb45487.x","article-title":"Treatment of severe myasthenia gravis with large doses of ACTH","volume":"135","author":"Reis","year":"1966","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD002828.pub2-BIB0050|cit50","first-page":"412","article-title":"Benefit from alternate-day prednisone in myasthenia gravis","volume":"21","author":"Warmolts","year":"1971","journal-title":"Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002828.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:31:44Z","timestamp":1764761504000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002828.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,4,20]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002828.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,20]]}}}